Das M, Musetti S, Huang L. RNA interference-based cancer drugs: the roadblocks, and the "delivery" of the promise. Nucleic Acid Ther. 2019 Apr;29(2):61-6. doi: 10.1089/nat.2018.0762
Winfree KB, Ainsworth C, Njue A, Molife C, Lyall M, Jen M-H, Bittoni M, Heyes A, Carbone DP. Defining aggressive disease in patients with advanced NSCLC receiving second-line treatment: a systematic review. Poster presented at the IASLC 19th World Conference on Lung Cancer; September 26, 2018. Toronto, Canada. [abstract] J Thorac Oncol. 2018 Oct; 13(10 (Suppl)):5908. doi: 10.1016/j.jtho.2018.08.1671
Karanth S, Rajan SS, Sharma G, Yamal JM, Morgan RO. Racial-ethnic disparities in end-of-life care quality among lung cancer patients: a SEER-medicare-based study. J Thorac Oncol. 2018 Aug;13(8):1083-93. doi: 10.1016/j.jtho.2018.04.014
Strickland A, Brogan AJ, Krauss J, Martindale R, Cresci G. Is the use of specialized nutritional formulations a cost-effective strategy? A national database evaluation. J Parenter Enter Nutr. 2005 Jan 1;29(1 Suppl):S81-91.